Cardiac fibroblast transcriptome analyses support a role for interferogenic, profibrotic, and inflammatory genes in

Robert M Clancy1, Androo J Markham2, Tanisha Jackson2

  • 1Division of Rheumatology, Department of Medicine, New York University School of Medicine, New York, New York robert.clancy@nyumc.org.

Insights

Maternal anti-Ro autoantibodies cause congenital heart block (CHB) by triggering Type I Interferon (IFN) responses in fetal heart fibroblasts. This leads to abnormal cardiac remodeling and fibrosis, contributing to CHB development.

Area of Science:

  • Cardiovascular Research
  • Immunology
  • Developmental Biology

Background:

  • Congenital heart block (CHB) is associated with SSA/Ro autoantibodies, characterized by cardiac fibrosis and macrophage infiltration.
  • Understanding the role of fibroblasts in CHB pathogenesis is crucial for developing targeted therapies.

Purpose of the Study:

  • To investigate the molecular mechanisms underlying fibroblast activation and cardiac fibrosis in SSA/Ro autoantibody-associated CHB.
  • To compare the transcriptomes of fetal cardiac fibroblasts in CHB and healthy hearts.

Main Methods:

  • In vitro simulation of cardiac injury using human fetal cardiac fibroblasts exposed to macrophage supernatants.
  • Transcriptome analysis of stimulated fibroblasts and fibroblasts isolated from fetal hearts with and without CHB.
  • Bioinformatic analysis (e.g., Database for Annotation, Visualization and Integrated Discovery) to identify differentially expressed genes.

Main Results:

  • Stimulated fibroblasts exhibited upregulated Type I Interferon (IFN) response genes and altered expression of fibrotic pathway genes.
  • In vivo analysis of CHB fetal hearts revealed upregulation of IFN response genes and matrix-related genes in fibroblasts.
  • ERK5 signaling pathway was implicated in the fibroblast response to injury.

Conclusions:

  • Upregulation of Type I IFN response genes in fetal cardiac fibroblasts contributes to abnormal cardiac remodeling and fibrosis in CHB.
  • This study provides novel in vitro and in vivo evidence supporting the role of Type I IFN in CHB pathogenesis.